The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: A systematic review and meta-analysis

Breast Cancer Research and Treatment

Volumn 144, Issue 2, 2014, Pages 223-232

  Petrelli, Fausto ^a   Coinu, Andrea ^a   Borgonovo, Karen ^a   Cabiddu, Mary ^a   Ghilardi, Mara ^a   Lonati, Veronica ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Breast cancer; Carboplatin; Cisplatin; Neoadjuvant chemotherapy; Pathologic complete response; Triple negative

Indexed keywords

CARBOPLATIN; CISPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT THERAPY; FEMALE; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84896544061     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2876-z     Document Type: Review

References (56)

1. Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275-1281
2. Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329-2334 (Pubitemid 46698581)
3. von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796-1804
4. Cortazar P, Zhang L, Untch M et al (2012) Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). Cancer Res 72:93
5. Perou CM (2010) Molecular stratification of triple-negative breast cancer. Oncologist 15(5s):39-48
6. Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1 positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28(375-379):18
7. Silver DP, Richardson AL, Eklund AC et al (2010) Efficacy of neoadjuvant cisplatin in triple negative breast cancer. J Clin Oncol 28:1145-1153
8. Sikov WM, Berry DA, Perou CM et al Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603(Alliance). http://www.abstracts2view.com/ sabcs13/view.php?nu=SABCS13L-458&terms. Accessed 20 Dec 2013
9. Von Minckwitz G, Schneeweiss A, Salat C et al (2013) A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol 31(suppl abstr):1004
10. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188 (Pubitemid 17189972)
11. Alba E, Chacon JI, Lluch A et al (2012) A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multi-center study. Breast Cancer Res Treat 136(2):487-493
12. Chang HR, Glaspy J, Allison MA et al (2010) Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 116(18):4227-4237
13. Chen XS, Nie XQ, Chen CM et al (2010) Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 21(5):961-967
14. Sikov WM, Dizon DS, Strenger R et al (2009) Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 27(28):4693-4700
15. Yerushalmi R, Hayes MM, Gelmon KA et al (2009) A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers. Clin Breast Cancer 9(3):166-172
16. Frasci G, Comella P, Rinaldo M et al (2009) Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 20(7):1185-1192
17. Torrisi R, Balduzzi A, Ghisini R et al (2008) Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 62(4):667-672
18. Julka PK, Chacko RT, Nag S et al (2008) A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer 98(8):1327-1335 (Pubitemid 351543585)
19. Sinclair NF, Abu-Khalaf NN, Rizack T et al (2012) Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR plus) and triple-negative (TN) breast cancer (BrCa): A BrUOG study. J Clin Oncol 30(15):1045
20. Shinde AM, Yim JH, Kruper L et al (2012) Pathologic complete response rates observed in women with locally advanced and inflammatory breast cancer receiving neoadjuvant carboplatin and paclitaxel. J Clin Oncol 30(15):1035
21. Rahal MM, Ramadan H, Hassan E et al (2010) Neoadjuvant platinum containing regimen for locally advanced triple negative breast cancer. Ann Oncol 21(8s):114-115
22. Diaz-Correa E, Singh C, Pereira S (2011) Neoadjuvant chemotherapy (NAC) consisting in dose-dense doxorubicin plus cyclophosphamide followed by cisplatin plus taxane for locoregional advanced triple-negative breast cancer (LATNBC). J Clin Oncol 29(suppl; abstr e11562)
23. Fei F, Du Y, Gu X et al (2012) A retrospective analysis of platinum-based neoadjuvant chemotherapy for local advanced triple negative breast cancer. Ann Oncol 23(9s):130
24. Mayer IA, Jovanovic B, Abramson VG et al A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC). http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L-397&terms. Accessed 20 Dec 2013
25. Rugo HS, Olopade O, DeMichele A et al Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL. http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L- 1400&terms
26. 2 in triple-negative breast cancer (TNBC). J Clin Oncol 31(suppl 26; abstr 149)
27. Zhang P, Yin Y, Xu B et al Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer: a phase II clinical trial. http://www.abstracts2view.com/sabcs13/ view.php?nu=SABCS13L-127&terms
28. Sirohi B, Arnedos M, Popat S et al (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19(11): 1847-1852
29. Kim HR, Jung KH, Im SA et al (2013) Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). Ann Oncol 24(6):1485-1490
30. Hurley J, Reis IM, Rodgers SE et al (2013) The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat 138(3):783-794
31. Roy V, Pockaj BA, Allred JB et al (2013) A phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer NCCTG study N0338. Am J Clin Oncol 36(6):540-544
32. Ithimakin S, Ratanawichitrasin A, Veerasarn V et al (2013) A phase II study of the combination of gemcitabine plus carboplatin as the neoadjuvant treatment in locally advanced breast cancer. J Med Assoc Thail 96(suppl 2):S67-S74
33. Snider JN, Sachdev JC, Allen JW et al (2012) Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC). J Clin Oncol 31(suppl): abstr 1068
34. Tiley S, Raab RE, Bellin LS et al (2012) Results of the East Carolina Breast Center phase II trial of neoadjuvant metronomic chemotherapy in triple-negative breast cancer (NCT00542191). J Clin Oncol 30(15 suppl 1):e11550
35. Telli ML, Kurian AW, Jensen KC et al (2011) A phase II study of gemcitabine and carboplatin (GC) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer. Cancer Res 71(24 suppl 3):abstract P3-14-08
36. Mrozek E, Lustberg MB, Knopp MV et al (2010) Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). J Clin Oncol 28(15 suppl 1):abstr 604
37. Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25-32
38. Piccart-Gebhart M, Holmes AP, de Azambuja E et al The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06). http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L-877&terms. Accessed 20 Dec 2013
39. Greenup R, Buchanan A, Lorizio W et al (2013) Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counselling cohort. Ann Surg Oncol 20(10):3254-3258
40. Bayraktar S, Gutierrez-Barrera AM, Liu D et al (2011) Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-153
41. Lips EH, Mulder L, Oonk A et al (2013) Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 108(10):2172-2177
42. Masuda H, Baggerly KA, Wang Y et al (2013) Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19(19):5533-5540
43. Gerber B, Loibl S, Eidtmann H et al (2013) Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 24(12):2978-2984
44. Bernsdorf M, Ingvar C, Jörgensen L et al (2011) Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat 126(2):463-470
45. von Minckwitz G, Blohmer JU, Costa SD et al (2013) Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 31(29):3623-3630
46. Balko JM, Giltnane J, Wang K et al (2013) Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 19(23):6353
47. Koolen BB, Pengel KE, Wesseling J et al (2014) Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 41(1):32-40
48. Groheux D, Hindié E, Giacchetti S et al (2012) Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med 53(2):249-254
49. Denkert C, Loibl S, Müller BM et al (2013) Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 24(11):2786-2793
50. Abdel-Fatah TM, Perry C, Dickinson P et al (2013) Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann Oncol 24(11):2801-2807
51. Dennison JB, Molina JR, Mitra S et al (2013) Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 19(13):3703-3713
52. Li XR, Liu M, Zhang YJ et al (2011) CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol 28(Suppl 1):S129-S134
53. Sakuma K, Kurosumi M, Oba H et al (2011) Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer. Exp Ther Med 2(2):257-264
54. Huober J, von Minckwitz G, Denkert C et al (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133-140
55. Liu M, Mo QG, Wei CY et al (2013) Platinum-based chemotherapy in triple-negative breast cancer: a meta-analysis. Oncol Lett 5(3):983-991
56. Carrick S, Ghersi D, Wilcken N, Simes J (2004) Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 3:CD003374